We are committed to tackling
biofilm-related disorders.

Read more

We combat biofilm-related disorders, including chronic and acute infections, and tackle antimicrobial resistance at its root cause

We do this by using proprietary compounds with proven anti-biofilm properties

“Biofilm provides the compatible conditions for horizontal gene transfer, such as high cell density, increased genetic competence and accumulation of genetic elements or uptake of resistance genes”

Slide 80%

of all chronic infections are associated with biofilm
Slide ~10MLN

annual deaths estimated to be caused by AMR globally by 2050 given the current progression trajector
Slide $100-400K

average additional hospital spend to treat a patient infected by resistant bacteria in OECD
Slide $2.9TRN

total estimated GDP effect in OECD due to antimicrobial resistance by 2050
Slide Only 6

new antibiotic drugs approved by FDA between 2010 and 2014 (41 cancer drug approvals in the same period)

Quorum sensing (QS) is a mechanism that enables microbial communication. It is based on the constant secretion of signaling molecules to the environment

The main role of QS is the regulation of vital processes in the cell such as virulence factor production or biofilm formation

Cell communication (AHV International, 2020 – based on Bassler / Keulemans, De Volkskrant, 2017)


Bacteria release signal molecules, which land on the receptors of similar bacteria (see magnification). This process is similar to gears that fit together


If more molecules are measured around the bacteria, the behavior of this group of bacteria changes


They will then, for example, emit light or produce mucus (biofilm)

How bacteria talk

Bonnie Lynn Bassler is an American molecular biologist who has researched chemical communication between bacteria known as quorum sensing, and contributed to the idea that disruption of chemical signaling can be used as an antimicrobial therapy.

HHV Biotech announces the successful completion of GMP manufacturing of its lead drug candidate; HHV-001
Due to a specific purification method that was employed, HHV was able to obtain a larger volume of drug substance than expected, at the desired purity. The amount produced is sufficient to complete pre-clinical activities required to build the IND dossier, as well as to start the human clinical development program.

March 14, 2022
Read full press release here.

HHV Biotech proudly joined as a member of the BEAM alliance
Launched in June 2015, the BEAM alliance (Biotech companies from Europe innovating in Anti-Microbial resistance research) represents 69 companies from 16 European countries, including Israel. These companies are involved in developing innovative products and kits to tackle antimicrobial resistance (AMR), including small molecule antibiotics, biologics, products with a prophylaxis indication, microbiome-based and phage-based therapies, immune targeting therapies, anti-biofilm agents, and medical devices including in-vitro diagnostics. We look forward to strengthening the consortium through active participation in meetings and a commitment to pursuing high-quality research.

February 11, 2022
Read more about the BEAM alliance and its members here.

HHV Biotech Announces the Appointment of Peter Nibbering, Ph.D., as Chief Scientific Officer
“Peter’s 30 years of experience researching and understanding the defense against infections, including biofilm-related infections, makes him an ideal fit as HHV Biotech’s CSO,” said Kim Bruin,Chief Executive Officer of HHV Biotech.

October 14, 2021
Read full press release here.

We are always open to partnership opportunities that complement our platform and we are continuously looking for new talents

Get in touch with us to find out more about our career opportunities


Leiden Bio Science Park
Mendelweg 32
2333 CS Leiden
The Netherlands